Day 1  
August 29, 2016

08:30-09:30  Registrations  
Hall- Allatoona

09:45-10:05  Opening Ceremony

Keynote Forum

10:05-10:10  Introduction
10:10-11:10  Parenteral drug delivery systems for insoluble drugs  
Jim Jingjun Huang, Ascendia Pharmaceuticals, USA

Group photo

Networking and Refreshments Break: 11:10-11:25 @ Foyer

11:25-12:25  Hybrid-Nanoengineering™: A new platform for nanomedicine  
Mewa Singh, Meda Biotech LLC, USA

Sessions:  
Challenges in Drug Development | Bioavailability Studies | Assessment of Bioequivalence |  
Clinical Pharmacology and Therapeutics

Session Chair: Akwete Lex Adjei, Rhodes Pharmaceuticals L.P, USA  
Session Co-chair: Muneesh Garg, Sitec Labs. Pvt. Ltd., India

12:30-13:00  New analytical methodology in assessing comparability of biosimilars  
Julia Ding, PPD Labs, USA

Lunch Break: 13:00-14:00 @ Foyer

14:00-14:30  Design and synthesis of potential ribonucleotide reductase enzyme (RNR) inhibitors as antileukemic and/or antiviral 2’-deoxymethylene nucleosides  
Khairia M Youssef, Future University, Egypt

14:30-15:00  Risk assessment with the help of FMEA analysis in BE studies  
Kateryna Zupanets, National University of Pharmacy, Ukraine

15:00-15:30  Some aspects of clinical trials on bioequivalence studies  
Kateryna Zupanets, National University of Pharmacy, Ukraine

15:30-16:00  Bioequivalence of Ipratropium Bromide HFA pMDI 20 µg/ actuation in healthy volunteers with and without charcoal blockade; and with spacer device  
Muneesh Garg, Sitec Labs. Pvt. Ltd., India

Networking and Refreshments Break: 16:00-16:15 @ Foyer

16:15-16:45  Prasugrel effect on in vitro bleeding time tests in a single dose bioequivalence study  
Ahmet Inal, Erciyes University, Turkey

16:45-17:15  Audits and Inspections - bioavailability and bioequivalence studies  
Bipin Patel, RSServe, India

17:15-17:45  The use of asymmetric distributions in average bioequivalence  
Roberto Molina de Souza, University of Parana, Brazil

Panel Discussion

Day 2  
August 30, 2016

Hall- Allatoona

Keynote Forum

10:00-11:00  Steady-state bioavailability of extended-release Methylphenidate capsules vs. immediate-release Methylphenidate tablets in healthy adult volunteers  
Akwete Lex Adjei, Rhodes Pharmaceuticals L.P, USA
### Session Introduction

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
</table>
| 11:15-11:45   | Accelerating preclinical development for poorly bioavailable compounds by assessing multiple oral technologies in parallel  
Stephen Tindal, Catalent, USA |
| 11:45-12:15   | Starch-guar gum extrudates: Microstructure, physicochemical properties and in vitro digestion  
Erich von Borries Medrano, Instituto Politecnico Nacional, Mexico |

### Poster Presentations @ 12:15-12:45

| BABE-001 | Suggestions for stage I of clinical trials of Diclocor  
Oleksii Popov, National University of Pharmacy, Ukraine |
| BABE-002 | Micellar liquid chromatographic determination of Lamivudine, Indinavir and Ketoconazole in dosage forms and biological fluids  
Wael Talaat, Damanhour University, Egypt |

### Lunch Break: 13:00-13:50 @ Foyer

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
</table>
| 13:50-14:20   | Overview of bioavailability/bioequivalence clinical trials in a phase 1 in Turkey  
Zafer Sezer, Ercyes University, Turkey |
| 14:20-14:50   | Structural approaches for targeted therapy  
Somdutta Saha, GlaxoSmithKline, USA |
| 14:50-15:20   | Development of sustained release antifungal, anti/protozoa and antimicrobial products in horses using hydrogels and extended release formulations in veterinary medicine  
Sue Duran, Auburn University, USA |

### Panel Discussion

### Networking and Refreshments Break: 16:30-16:50 @ Foyer

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>11:00-11:15</td>
<td>Networking and Refreshments Break: 11:00-11:15 @ Foyer</td>
</tr>
</tbody>
</table>
| 11:15-11:45   | Accelerating preclinical development for poorly bioavailable compounds by assessing multiple oral technologies in parallel  
Stephen Tindal, Catalent, USA |
| 11:45-12:15   | Starch-guar gum extrudates: Microstructure, physicochemical properties and in vitro digestion  
Erich von Borries Medrano, Instituto Politecnico Nacional, Mexico |

### Poster Presentations @ 12:15-12:45

| BABE-001 | Suggestions for stage I of clinical trials of Diclocor  
Oleksii Popov, National University of Pharmacy, Ukraine |
| BABE-002 | Micellar liquid chromatographic determination of Lamivudine, Indinavir and Ketoconazole in dosage forms and biological fluids  
Wael Talaat, Damanhour University, Egypt |

### Lunch Break: 13:00-13:50 @ Foyer

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
</table>
| 13:50-14:20   | Overview of bioavailability/bioequivalence clinical trials in a phase 1 in Turkey  
Zafer Sezer, Ercyes University, Turkey |
| 14:20-14:50   | Structural approaches for targeted therapy  
Somdutta Saha, GlaxoSmithKline, USA |
| 14:50-15:20   | Development of sustained release antifungal, anti/protozoa and antimicrobial products in horses using hydrogels and extended release formulations in veterinary medicine  
Sue Duran, Auburn University, USA |

### Panel Discussion

### Networking and Refreshments Break: 16:30-16:50 @ Foyer

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>11:00-11:15</td>
<td>Networking and Refreshments Break: 11:00-11:15 @ Foyer</td>
</tr>
</tbody>
</table>
| 11:15-11:45   | Accelerating preclinical development for poorly bioavailable compounds by assessing multiple oral technologies in parallel  
Stephen Tindal, Catalent, USA |
| 11:45-12:15   | Starch-guar gum extrudates: Microstructure, physicochemical properties and in vitro digestion  
Erich von Borries Medrano, Instituto Politecnico Nacional, Mexico |

### Poster Presentations @ 12:15-12:45

| BABE-001 | Suggestions for stage I of clinical trials of Diclocor  
Oleksii Popov, National University of Pharmacy, Ukraine |
| BABE-002 | Micellar liquid chromatographic determination of Lamivudine, Indinavir and Ketoconazole in dosage forms and biological fluids  
Wael Talaat, Damanhour University, Egypt |

### Lunch Break: 13:00-13:50 @ Foyer

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
</table>
| 13:50-14:20   | Overview of bioavailability/bioequivalence clinical trials in a phase 1 in Turkey  
Zafer Sezer, Ercyes University, Turkey |
| 14:20-14:50   | Structural approaches for targeted therapy  
Somdutta Saha, GlaxoSmithKline, USA |
| 14:50-15:20   | Development of sustained release antifungal, anti/protozoa and antimicrobial products in horses using hydrogels and extended release formulations in veterinary medicine  
Sue Duran, Auburn University, USA |

### Panel Discussion

### Networking and Refreshments Break: 16:30-16:50 @ Foyer

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>11:00-11:15</td>
<td>Networking and Refreshments Break: 11:00-11:15 @ Foyer</td>
</tr>
</tbody>
</table>
| 11:15-11:45   | Accelerating preclinical development for poorly bioavailable compounds by assessing multiple oral technologies in parallel  
Stephen Tindal, Catalent, USA |
| 11:45-12:15   | Starch-guar gum extrudates: Microstructure, physicochemical properties and in vitro digestion  
Erich von Borries Medrano, Instituto Politecnico Nacional, Mexico |

### Poster Presentations @ 12:15-12:45

| BABE-001 | Suggestions for stage I of clinical trials of Diclocor  
Oleksii Popov, National University of Pharmacy, Ukraine |
| BABE-002 | Micellar liquid chromatographic determination of Lamivudine, Indinavir and Ketoconazole in dosage forms and biological fluids  
Wael Talaat, Damanhour University, Egypt |

### Lunch Break: 13:00-13:50 @ Foyer

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
</table>
| 13:50-14:20   | Overview of bioavailability/bioequivalence clinical trials in a phase 1 in Turkey  
Zafer Sezer, Ercyes University, Turkey |
| 14:20-14:50   | Structural approaches for targeted therapy  
Somdutta Saha, GlaxoSmithKline, USA |
| 14:50-15:20   | Development of sustained release antifungal, anti/protozoa and antimicrobial products in horses using hydrogels and extended release formulations in veterinary medicine  
Sue Duran, Auburn University, USA |

### Panel Discussion

### Networking and Refreshments Break: 16:30-16:50 @ Foyer

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>11:00-11:15</td>
<td>Networking and Refreshments Break: 11:00-11:15 @ Foyer</td>
</tr>
</tbody>
</table>
| 11:15-11:45   | Accelerating preclinical development for poorly bioavailable compounds by assessing multiple oral technologies in parallel  
Stephen Tindal, Catalent, USA |
| 11:45-12:15   | Starch-guar gum extrudates: Microstructure, physicochemical properties and in vitro digestion  
Erich von Borries Medrano, Instituto Politecnico Nacional, Mexico |

### Poster Presentations @ 12:15-12:45

| BABE-001 | Suggestions for stage I of clinical trials of Diclocor  
Oleksii Popov, National University of Pharmacy, Ukraine |
| BABE-002 | Micellar liquid chromatographic determination of Lamivudine, Indinavir and Ketoconazole in dosage forms and biological fluids  
Wael Talaat, Damanhour University, Egypt |

### Lunch Break: 13:00-13:50 @ Foyer

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
</table>
| 13:50-14:20   | Overview of bioavailability/bioequivalence clinical trials in a phase 1 in Turkey  
Zafer Sezer, Ercyes University, Turkey |
| 14:20-14:50   | Structural approaches for targeted therapy  
Somdutta Saha, GlaxoSmithKline, USA |
| 14:50-15:20   | Development of sustained release antifungal, anti/protozoa and antimicrobial products in horses using hydrogels and extended release formulations in veterinary medicine  
Sue Duran, Auburn University, USA |

### Panel Discussion

### Networking and Refreshments Break: 16:30-16:50 @ Foyer

### Lunch Break: 13:15-14:00 @ Foyer

### Panel Discussion

### Awards Ceremony

---

**Bookmark your dates**

8th World Congress on

**Bioavailability & Bioequivalence: BA/BE Studies Summit**

June 26-28, 2017 San Diego, USA

e-mail: babe@conferenceseries.net

Website: bioavailability-bioequivalence.pharmaceuticalconferences.com